Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RLY-1971 · 1 trial · 1 indication
MTD is defined as a dose level immediately below that at which ≥2 of 6 subjects experience a DLT during the first cycle.
RP2D may be the same dose level or lower than the determined MTD.
| Arm | Type | Description |
|---|---|---|
| RLY-1971 - Dose Escalation/Expansion | EXPERIMENTAL | Dose Escalation: Oral dose of RLY-1971 until Maximum Tolerated Dose (MTD), and Recommended Phase 2 dose (RP2D) are identified Dose Expansion: Oral dose of RLY-1971 once Maximum Tolerated Dose (MTD), and Recommended Phase 2 Dose (RP2D) are identified. |
| Name | Type | Description |
|---|---|---|
| RLY-1971 | DRUG | RLY-1971 is an oral inhibitor of SHP2. |
Inclusion Criteria: Subject is willing and able to provide written informed consent for the study prior to the performance of any study-specific procedures Subject is a male or female subject ≥18 years of age at the time of consent Subject must have an ECOG PS ≤ 1 Subject must have histologically o...
RLY-1971 is an investigational small molecule being studied for the treatment of solid tumors in adults. It is intended for patients with advanced or metastatic solid tumors, as evaluated in a Phase 1 clinical trial.
RLY-1971 is being developed by Roche Holding AG, a biopharmaceutical company. The company's stock is traded under the ticker symbol RHHBY.
RLY-1971 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed.
RLY-1971 has been studied in a Phase 1 clinical trial with the identifier NCT04252339. This trial, titled "RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors," enrolled 56 participants in the United States and has been completed.
No alternative names for RLY-1971 have been reported. It is known solely by its code name RLY-1971 in clinical development.